Hong Kong Professional Services Stock News

Why this dual drug news matters for CSPC Pharmaceutical Group (SEHK:1093) CSPC Pharmaceutical Group (SEHK:1093) has just reported two pipeline milestones, US and China trial approvals for its aldosterone synthase inhibitor SYH2072 in hypertension and a fresh China filing for a fixed dose diabetes combination. For investors, these updates highlight activity in both early clinical development and late stage commercial readiness. This helps frame how the stock might reflect CSPC's current...

Lenovo Group (SEHK:992) has just expanded its education and retail technology offerings, announcing new Chromebook models for classrooms alongside AI powered Smart Store Services and AI Retail Assistants aimed at retailers’ operations and customer interactions. See our latest analysis for Lenovo Group. These education and retail launches come after a tougher period for the shares, with a 90 day share price return of 23.26% decline and a 1 year total shareholder return of 3.02% decline. This...

Earlier this month, Akeso announced that China’s National Medical Products Administration accepted its supplemental New Drug Application for gumokimab (AK111), an anti‑IL‑17A antibody for active ankylosing spondylitis, supported by positive Phase III data. This milestone highlights Akeso’s expanding non‑oncology portfolio and the potential for gumokimab to address a large ankylosing spondylitis patient population in China. We’ll now examine how gumokimab’s sNDA acceptance, supported by...

Why Pop Mart’s new buyback is back in focus Pop Mart International Group (SEHK:9992) has kicked off a sizeable share repurchase program, targeting up to 10% of its issued capital after shareholder approval, and the move has quickly sharpened market attention. See our latest analysis for Pop Mart International Group. The buyback news landed on a market already seeing a sharp swing in sentiment, with a 7 day share price return of 22.96% and a 1 year total shareholder return of 140.99% following...

Key Insights Significant insider control over Skyworth Group implies vested interests in company growth The largest...

Key Insights Significant control over VISEN Pharmaceuticals by public companies implies that the general public has...

With its stock down 15% over the past three months, it is easy to disregard TUHU Car (HKG:9690). But if you pay close...

Recent performance snapshot CK Hutchison Holdings (SEHK:1) has drawn investor attention after a strong share price move, with returns of 1.4% over the past day, 3.8% over the past week, and 13.6% over the past month. See our latest analysis for CK Hutchison Holdings. Set against a 1 year total shareholder return of 67.9% and a 22.8% 3 month share price return, the recent move suggests momentum has been building as investors reassess both growth potential and risks for CK Hutchison Holdings at...

Most readers would already be aware that EPS Creative Health Technology Group's (HKG:3860) stock increased...

While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Ching Lee Holdings Limited's ( HKG:3728 ) price-to-earnings (or "P/E") ratio of 7.5x might make it look like a buy...

With a median price-to-earnings (or "P/E") ratio of close to 13x in Hong Kong, you could be forgiven for feeling...

While Huili Resources (Group) Limited ( HKG:1303 ) shareholders are probably generally happy, the stock hasn't had...

Viva Biotech Holdings ( HKG:1873 ) shareholders are no doubt pleased to see that the share price has bounced 28% in the...

JTF International Holdings Limited ( HKG:9689 ) shareholders have had their patience rewarded with a 54% share price...

Despite an already strong run, Sheung Yue Group Holdings Limited ( HKG:1633 ) shares have been powering on, with a gain...

Key Insights The considerable ownership by private companies in China National Building Material indicates that they...

Despite an already strong run, Vision Values Holdings Limited ( HKG:862 ) shares have been powering on, with a gain of...

Key Insights The considerable ownership by individual investors in Shanghai Fudan Microelectronics Group indicates that...

Why WH Group Is On Investors’ Radar Today WH Group (SEHK:288) has drawn attention after a period where its share price performance and fundamentals tell a mixed story, inviting investors to reassess how its valuation lines up with recent business results. See our latest analysis for WH Group. While WH Group’s share price is close to HK$8.79 after a modest 0.11% 1 day share price return, the 18.78% 90 day share price return and 63.87% 1 year total shareholder return suggest momentum has...

China Unicom (Hong Kong) Limited recently appointed Dong Xin as both Chairman and Chief Executive Officer, effective January 14, 2026, consolidating its top leadership roles under a single executive. By bringing in the existing head of China United Network Communications Group and China United Network Communications Corporation, the company is tightening alignment with its state-owned parent structure, which could influence future corporate priorities and governance. We will now examine...

In recent months, Chinese automaker BYD accelerated its global push by shipping over 5,800 electric and hybrid vehicles to Argentina, capitalizing on President Javier Milei’s tariff-free quota for imported EVs. This move underlines BYD’s cost-focused business model: the company is sacrificing premium-level margins to build global scale and accessible pricing, while gradually layering in higher-end models and software features. Next, we’ll explore how BYD’s Argentina expansion under...

WuXi Biologics recently announced that its Wuxi Drug Product Facility 5 and Drug Product Packaging Center received UK MHRA GMP certifications for commercial ophthalmic biologic manufacturing, alongside the launch of its PatroLabTM digital twin platform for real-time bioprocess monitoring and control. Together, these developments highlight WuXi Biologics’ growing role as a globally compliant manufacturer that is integrating advanced digital technologies to enhance biologics quality and...